See more : Kangqiao Service Group Limited (2205.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Biodesix, Inc. (BDSX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodesix, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- BlackWall Limited (BWF.AX) Income Statement Analysis – Financial Results
- Big River Industries Limited (BRI.AX) Income Statement Analysis – Financial Results
- Myhome Real Estate Development Group Co., Ltd. (000667.SZ) Income Statement Analysis – Financial Results
- Iconovo AB (publ) (ICO.ST) Income Statement Analysis – Financial Results
- Crane Infrastructure Limited (CRANEINFRA.BO) Income Statement Analysis – Financial Results
Biodesix, Inc. (BDSX)
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.09M | 38.21M | 54.51M | 45.56M | 24.55M | 20.43M |
| Cost of Revenue | 13.01M | 14.15M | 30.52M | 22.00M | 6.07M | 4.41M |
| Gross Profit | 36.08M | 24.06M | 23.99M | 23.56M | 18.48M | 16.03M |
| Gross Profit Ratio | 73.50% | 62.96% | 44.01% | 51.71% | 75.26% | 78.44% |
| Research & Development | 9.99M | 13.10M | 12.79M | 10.82M | 10.47M | 8.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 30.64M | 25.90M |
| Selling & Marketing | 0.00 | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| SG&A | 67.39M | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| Other Expenses | 44.00K | 109.00K | -9.00K | 422.00K | -2.38M | -1.24M |
| Operating Expenses | 77.42M | 74.56M | 63.31M | 45.68M | 41.11M | 34.09M |
| Cost & Expenses | 90.43M | 88.72M | 93.82M | 67.67M | 47.18M | 38.49M |
| Interest Income | 0.00 | 8.07M | 4.51M | 18.00K | 55.00K | 24.00K |
| Interest Expense | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Depreciation & Amortization | 5.51M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -37.10M | -53.78M | -35.47M | -20.84M | -24.93M | -21.51M |
| EBITDA Ratio | -75.59% | -131.89% | -72.15% | -47.58% | -90.25% | -85.81% |
| Operating Income | -41.34M | -50.51M | -39.32M | -22.12M | -22.63M | -23.46M |
| Operating Income Ratio | -84.22% | -132.17% | -72.14% | -48.55% | -92.16% | -114.82% |
| Total Other Income/Expenses | -10.80M | -14.86M | -2.22M | -8.42M | -3.99M | -2.71M |
| Income Before Tax | -52.15M | -65.45M | -43.16M | -31.35M | -30.73M | -26.17M |
| Income Before Tax Ratio | -106.23% | -171.27% | -79.18% | -68.81% | -125.15% | -128.06% |
| Income Tax Expense | 0.00 | 14.94M | 1.32M | 5.12M | 629.00K | 211.00K |
| Net Income | -52.15M | -80.39M | -44.48M | -36.47M | -31.36M | -26.17M |
| Net Income Ratio | -106.23% | -210.37% | -81.61% | -80.06% | -127.71% | -128.06% |
| EPS | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| Weighted Avg Shares Out | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
| Weighted Avg Shares Out (Dil) | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
4 Stocks Insiders Are Buying
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2021 Results - Earnings Call Transcript
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test
Source: https://incomestatements.info
Category: Stock Reports